Newsfeeds Archive - Spark Newswire

1 minute read

SciSparc- Clearmind Collaboration Evolves With New International Patent Application For Preventing And Treating Depression

March 27, 8:56 AM

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system,

CMND

2 minute read

Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome

By Vuk Zdinjak

June 16, 8:46 AM

Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:CMND) (FSE:CWY) announced that as part of the company's ongoing collaboration with SciSparc Ltd.

CMND

1 minute read

Clearmind Medicine Forms A Data And Safety Monitoring Board To Oversee Its First-In-Human Clinical Trial

By Happy Mohamed

April 27, 8:40 AM

Clearmind Medicine Inc. (NASDAQ:CMND) (CSE:CMND), (FSE: CWY) ("Clearmind" or "the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve

CMND

1 minute read

SciSparc And Clearmind Collaboration Strengthens IP Portfolio With Patent Application For Treatment Of Depression

By Vuk Zdinjak

April 21, 9:12 AM

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its ongoing collaboration with Clearmind Medicine Inc. (NASDAQ:

CMND

1 minute read

News

SciSparc and Clearmind Collaboration Strengthens IP Portfolio With Patent Application In The U.S. For Treatment Of Depression

By Happy Mohamed

April 21, 8:32 AM

The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™ TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC)

CMND

1 minute read

Clearmind Medicine Announces Pricing Of $3.5M Public Offering Of 4,505,718 Common Shares And Pre-Funded Warrants At A Price Of $0.78/Share

By Happy Mohamed

April 4, 9:06 AM

Clearmind Medicine Inc. (NASDAQ:CMND) (CSE:CMND), (FSE: CWY) ("Clearmind"), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated

CMND

4 minute read

Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More

By Lara Goldstein

March 20, 5:11 PM

Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered

BRAXF

1 minute read

FDA
News

Israel-Based Clearmind Medicine Successfully Completes Production Of CMND-100 Drug Candidate For Clinical Trial

By Benzinga Newsdesk

January 10, 9:43 AM

Clearmind Medicine Inc. (NASDAQ:CMND) (CSE:CMND) (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve

CMND

2 minute read

Clearmind Announces Initiation Of CMND-100 Manufacturing Program To Address Its Upcoming Clinical Trial

By Benzinga Newsdesk

November 23, 9:45 AM

Clearmind Medicine Inc. (NASDAQ:CMND), (CSE:CMND), (FSE: CWY) ("Clearmind" or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve

CMND

2 minute read

Clearmind Medicine Priced ~1.15M Share Public Offering of Common Stock Monday at $6.50/Share and is being Uplisted to the Nasdaq Capital Market on November 15

By Charles Gross

November 15, 6:26 AM

Clearmind Medicine Inc.

CSE:CMND